Against the backdrop of Vienna’s historic charm, BIOTECH AUSTRIA, the association for the Austrian biotech industry,
recently invited leading industry representatives to the Vienna Stock Exchange to mark the third anniversary of the association.

Automation: SLAS empowers the global life sciences community to transform research by bringing interdisciplinary researchers and technology providers together to learn, solve challenges and advance life sciences innovation.

Expanding networks: Comprised of passionate individuals committed to driving positive change, YEBN board brings a wealth of diverse experiences and expertise to guide the association towards new heights of success.

French Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens.

European Commission President Ursula von der Leyen has revealed her nominees for new commissioners to lead the bloc for the next term from 2024 to 2029.

Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.

Austria has once again come a little closer to its goal of achieving the highest research and development rate (R&D rate) in the EU. Two thirds of R&D investments are made by industry, of which around 16% are made by foreign companies. Two current examples of investments in Austria from the life sciences sector are Novartis and Ligand Pharmaceuticals.

After three and a half years of construction, the CDMO Richter Biologics has inaugurated its new multipurpose production facility that triples the CDMO’s capacity for the bacterial production of pDNA, vaccines, nanobodies and recombinant proteins.

British protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes.

Agri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide.